Evidence map›Paper›PMID 41412872›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2026

Evaluating the association of antibiotic spectrum and treatment responses of cystic fibrosis pulmonary exacerbations.

Ranjani Somayaji, Jonathan D Cogen, Donald VanDevanter, John J LiPuma, Natalie E West, Don B Sanders, Jeffrey S Gerber, Matthew P Kronman, Christopher H Goss, Patrick A Flume and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ranjani SomayajiDepartment of Medicine, University of Calgary, Calgary, Canada. Electronic address: rsomayaj@ucalgary.ca.
Jonathan D CogenDivision of Pulmonary and Sleep Medicine, Department of Pediatrics, Center for Respiratory Biology and Therapeutics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Donald VanDevanterDepartment of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
John J LiPumaDepartment of Pediatrics, University of Michigan Medical School, Ann Arbor, MI, USA.
Natalie E WestDepartment of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Don B SandersDivision of Pediatric Pulmonology, Allergy and Sleep Medicine, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA.
Jeffrey S GerberDivision of Infectious Diseases, Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Matthew P KronmanDivision of Infectious Diseases, Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA.
Christopher H GossDivision of Pulmonary and Sleep Medicine, Department of Pediatrics, Center for Respiratory Biology and Therapeutics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA USA; Cystic Fibrosis Therapeutics Development Network, Seattle Children's Research Institute, Seattle, WA USA.
Patrick A FlumeMedical University of South Carolina, Charleston, SC, USA.
Sonya L HeltsheDivision of Pulmonary and Sleep Medicine, Department of Pediatrics, Center for Respiratory Biology and Therapeutics, Seattle Children's Hospital, University of Washington, Seattle, WA, USA; Cystic Fibrosis Therapeutics Development Network, Seattle Children's Research Institute, Seattle, WA USA.

Funding

Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4M
The South Carolina Clinical & Translational Research Institute (SCTR)UM1TR005294 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI KATHLEEN T. BRADY, PATRICK A FLUME · 2025 to 2026
$7.6M
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CFUM1HL119073 · NHLBI · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER, SINGH, PRADEEP K · 2013 to 2017
$4.8M
Investigating treatment resistance mechanisms in chronic bacterial infectionsR01AI101307 · NIAID · UNIVERSITY OF WASHINGTON · PI BRUCE, JAMES EDWARD, MANOIL, COLIN · 2012 to 2016
$2.9M
Regulation of host inflammatory responses and outcome in melioidosis by TLR5R01HL113382 · NHLBI · UNIVERSITY OF WASHINGTON · PI WEST, TIMOTHY EOIN · 2012 to 2016
$2.6M
NCATS NIH HHS UM1 TR005294NHLBI NIH HHS R01 HL113382NHLBI NIH HHS UM1 HL119073NIAID NIH HHS R01 AI101307NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

introductionWhile antibiotics are routinely prescribed for cystic fibrosis (CF) pulmonary exacerbation (PEx) treatment, little evidence exists informing optimal antibiotic selection. This study aimed to determine whether broader-spectrum antibiotics were associated with improved clinical outcomes compared to narrower-spectrum antibiotics for PEx treatment.

methodsA secondary analysis of the Standardizing Treatment of Pulmonary Exacerbation-2 (STOP-2) clinical trial was completed. Antibiotic spectrum was defined using the CF antibiotic spectrum index (CF-ASI), a tool that classifies each antibiotic's expected spectrum of antibacterial activity, and was categorized into quartiles (<14, 14-17, 18-22, and >23). Multivariable generalized linear and inverse probability weighted models were constructed to describe the association between ASI and relevant clinical outcomes, including pre- to post-PEx changes in lung function, weight, and CF symptoms scores.

resultsA total of 982 people with CF with a mean age of 30.3 years (SD 9.7) were available for analysis. The median CF-ASI score for the entire cohort was 17 (IQR 13-22). The mean ppFEV

conclusionsOpportunities exist to select narrower-spectrum antibiotics for PEx treatment in CF to minimize the risks of antibiotic toxicities.

Indexed as

Anti-Bacterial AgentsCystic FibrosisAdultDisease ProgressionFemaleHumansMaleRespiratory Function TestsTreatment OutcomeAnti-Bacterial AgentsAntibiotic spectrumCystic fibrosisPulmonary exacerbationStewardshipTreatment response

Identifiers

PMID41412872
PMCPMC13078416

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.